SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-21-000313
Filing Date
2021-03-15
Accepted
2021-03-15 14:52:30
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGEDWARD T. MATHERSFOREST BASKETTJOSHUA MAKOWERLIZA LANDSMANMOHAMAD H. MAKHZOUMINEA 17 GP, LLCNEA PARTNERS 17, L.P.NEW ENTERPRISE ASSOCIATES 17, L.P.PAUL WALKERPETER W. SONSINIRICK YANGSCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES 17, LLC / SATSUMA PHARMACEUTICALS -- 13D geo17-satsuma_18468.htm SC 13D 552042
  Complete submission text file 0001072613-21-000313.txt   554117
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Subject) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91126 | Film No.: 21741189
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities 17, LLC (Filed by) CIK: 0001790256 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D